Author: kodiac

Piperlongumine (piplartine, 5,6-dihydro-1-[(2E)-1-oxo-3-(3,4,5-trimethoxyphenyl)-2-propenyl]-2(1H)-pyridinone; CAS 20069-09-4; molecular formula C17H19NO5; molecular weight 317.34 g/mol) is an amide alkaloid constituent of the fruit, root, and stem of Piper longum L. (long pepper), a plant of the Piperaceae family native to the Indian subcontinent and Southeast Asia with a centuries-long history of use in Ayurvedic and traditional Chinese medicine. The compound was first isolated and structurally characterized by Chatterjee and Dutta in 1963 and remained a minor phytochemical curiosity until the landmark 2011 report by Raj et al. in Nature, which identified piperlongumine through an unbiased chemical screen as a small molecule that selectively kills cancer cells and oncogene-transformed cells but not normal cells by inducing the accumulation of reactive oxygen species (ROS), irrespective of p53 status or proliferation rate [1]. That demonstration catalyzed an extensive preclinical research literature that now spans more than two dozen cancer histologies, multiple molecular targets, and several emerging non-oncologic applications including senolytic clearance of senescent cells, neuroinflammation, and metabolic disease.

The molecular pharmacology of piperlongumine centers on its electrophilic alpha,beta-unsaturated carbonyl system, which reacts covalently with nucleophilic cysteine residues on multiple redox-regulatory and signaling proteins. Direct binding targets include glutathione S-transferase pi 1 (GSTP1), thioredoxin reductase 1 (TrxR1), and carbonyl reductase 1 (CBR1), whose inhibition impairs cellular antioxidant defenses and elevates intracellular ROS (principally hydrogen peroxide and superoxide) to levels that exceed the already elevated oxidative baseline of transformed cells [1, 2, 3]. Downstream consequences include ROS-dependent downregulation of specificity protein transcription factors Sp1, Sp3, and Sp4 and their pro-oncogenic target genes (cyclin D1, survivin, cMyc, EGFR, cMet) [4]; inhibition of the NF-kB signaling pathway with suppression of pro-inflammatory and pro-survival gene expression [5, 6]; direct inhibition of STAT3 phosphorylation and dimerization [7]; inhibition of PI3K/Akt/mTOR signaling with consequent promotion of autophagy and apoptosis [8, 9]; and blockade of NLRP3 inflammasome assembly through disruption of NLRP3-NEK7 association and NLRP3 oligomerization [10]. The compound has also been identified as a ligand for the orphan nuclear receptor NR4A1 (Nur77) [11]. The selectivity for cancer cells over normal cells is attributed to the higher basal ROS burden and the greater dependence on antioxidant buffering capacity in transformed cells; normal cells, operating at lower oxidative stress, tolerate the moderate ROS elevation induced by piperlongumine without reaching the apoptotic threshold.

Pharmacokinetic characterization in rodent models indicates oral bioavailability of approximately 50 to 76 percent (dose-dependent, inversely related to dose in the 5 to 10 mg/kg range in rats), low hepatic extraction ratio (E = 0.09), plasma protein binding of approximately 93 percent, and metabolism by multiple CYP isoenzymes producing several hydroxylated and demethylated metabolites [12, 13]. The compound exhibits poor aqueous solubility (approximately 26 micrograms per milliliter in water at ambient pH) but adequate solubility in dimethyl sulfoxide, ethanol, PEG 400, and lipid-based formulations. Stability is pH-dependent, with maximum stability near pH 4 and significant degradation at alkaline pH values and under ultraviolet irradiation [14]. No human pharmacokinetic data have been published; the compound has not entered formal clinical trials as of the most recent monograph revision, though the extensive preclinical evidence base and favorable rodent safety profile support advancement to first-in-human studies.

In vivo antitumor efficacy has been demonstrated in xenograft models of colorectal, pancreatic, lung, breast, head and neck, thyroid, prostate, and cervical cancers at intraperitoneal doses of 2.4 to 10 mg/kg per day, with significant tumor growth inhibition and no apparent systemic toxicity to normal tissues in treated animals [1, 15, 16, 17, 18]. Synergistic combinations with conventional chemotherapeutics (cisplatin, gemcitabine, paclitaxel, oxaliplatin, doxorubicin, 5-fluorouracil) have been reported across multiple tumor types, with the ROS-elevating mechanism of piperlongumine sensitizing resistant cells to cytotoxic therapy [19, 20, 21]. A second application of growing interest is the senolytic activity first reported by Wang et al. (2016), who demonstrated that piperlongumine selectively kills radiation-induced, replicative, and oncogene-induced senescent human WI-38 fibroblasts and synergizes with the BH3 mimetic ABT-263 in senescent cell clearance [22]. Subsequent medicinal chemistry optimization has produced piperlongumine analogs with up to 50-fold enhanced senolytic potency [23].

This monograph documents the chemistry, isolation, and synthesis of piperlongumine; the multi-target molecular pharmacology; the rodent pharmacokinetic profile; the preclinical antitumor and senolytic evidence base; the absence of clinical trial data and the translational considerations for first-in-human development; sourcing and quality verification; reconstitution and handling; stack-interaction considerations; adverse-event and safety signal from animal studies; and a structured comparative assessment of five pro-oxidant or senolytic natural products (withaferin A, sulforaphane, parthenolide, curcumin, fisetin) against piperlongumine on five competency standards.